Target Pair ◆ pd1-vegf-a
PD-1 × VEGF-ADRAFT
数据列表以英文版为准（Grade A/B 证据，见 gp-master）。
1 · 概览
活跃资产: 5 ｜ 公司: 5 ｜ 事件: 6
77
机会评分观察
≥80 黄金 / 65–79 观察 / <65 持有（五维加权，方法论见 gp-master）
2 · 为什么值得做
单一分子同时阻断 PD-1 检查点与 VEGF-A 血管生成；旗舰配对：ivonescimab/AK112（Akeso→Summit）中国获批×3、美国 BLA 审评中（PDUFA 2026-11-14）——本轮最具商业引力的双抗配对。
3 · 资产格局
- 01Ivonescimab/AK112 — Akeso→Summit, PD-1×VEGF, approved China ×3, US BLA under review (PDUFA 2026-11-14)
- 02CTX-10726 — Compass, preclinical
- 03CR-001 — Crescent, Phase 1/2
- 04SIM0689 — Simcere, IND 2026-06
- 05(adjacent red sea: pumitamig/BNT327, IMM2510 — PD-L1×VEGF, not this pair)
4 · 公司
- 01Akeso (origin)
- 02Summit Therapeutics (US partner, up to $5B deal 2022)
- 03Compass
- 04Crescent
- 05Simcere
5 · 临床与交易事件
| 日期 | 事件 | 公司 |
|---|---|---|
| 2022 | Summit–Akeso license (up to US$5B) | Summit/Akeso |
| 2024 | ivonescimab approvals in China (×2); BioNTech–Biotheus $800M upfront (adjacent PD-L1×VEGF) | Akeso/BioNTech |
| 2025-04 | HARMONi-2 OS (HR≈0.777) weaker than PFS implied — stock drop | Akeso/Summit |
| 2025-10 | HARMONi-3 interim OS miss + protocol amendment + canceled $500M share sale | Summit |
| 2026-08 | HARMONi-6 survival-benefit-narrowing reports at 3rd China approval | Akeso |
| 2026-11-14 | US BLA PDUFA date (ivonescimab) | FDA/Summit |
5b · 自动跟踪（clinicaltrials.gov）
| 日期 | 事件 | 资产 |
|---|---|---|
| 2026-08-19 | A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell HIGH | ivonescimab/AK112 |
| 2026-08-19 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer HIGH | ivonescimab/AK112 |
| 2026-08-19 | Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Li HIGH | ivonescimab/AK112 |
由 intel_ingest.py 自动摄取（Grade A，clinicaltrials.gov）；每周刷新、人工确认。
6 · 风险与失败
- 01HARMONi-2 OS (HR≈0.777) weaker than PFS implied; HARMONi-3 interim OS miss + protocol amendment
- 02Western-patient PFS weaker than China data
- 03HARMONi-6 survival-benefit-narrowing reports (Aug 2026)
- 04Class precedent failure: bintrafusp alfa (PD-L1×TGF-β) Phase 3 failure; ImmuneOnco–Axion >$2B license termination (PD-L1×VEGF)
- 05Single-asset concentration; exhaustive asset count incomplete (China undisclosed)
7 · 研发问题
- 01Pivotal OS numbers for HARMONi-3/-6 (paywalled/granularity)
- 02Western-patient efficacy vs China data (ethnicity/biology questions)
- 03Exhaustive preclinical PD-1×VEGF asset count (China undisclosed)
- 04Differentiation vs PD-L1×VEGF (pumitamig) in the clinic
8 · 研究工具
- 01PD-1 (PDCD1) ECD — mature formats
- 02VEGF-A ECD (VEGFA) — mature formats
- 03Human/Cyno cross-species
- 04Dual-binding SPR/BLI panel
- 05Reference: bevacizumab-class anti-VEGF, pembrolizumab-class anti-PD-1
9 · 实验工作流
结合 → 双结合 → 功能（PRD §20 §9）。
10 · 服务
11 · 证据
最近审校: 2026-08-19 ｜ 置信度: medium ｜ 证据: Score 77/100 草案：PRD §7 阈值=Watch，旗舰样板建议 Golden——待创始人校准；Grade A/B only（AZ $15B 传闻=Grade D 不入公开）
完整证据台账: gp-master/GP-01_pd1-vegf-a.md（本仓库 docs/artifacts/gp-master/，未托管外链）
下一步